[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Trexo Robotics Holdings Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":78},{"warningLetters":4,"total":77},[5,32,55],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1434,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-06-04T20:30:00Z\">06\u002F04\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-07T05:00:00Z\">02\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrexo-robotics-holdings-inc-673150-02072024\">Trexo Robotics Holdings Inc.\u003C\u002Fa>","&quot;OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality&quot;","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device, Misbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Manmeet Maggu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Trexo Robotics Holdings Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6705 Millcreek Drive, Unit 3\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mississauga\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>L5N 5M4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@trexorobotics.com\"> (b)(6)@trexorobotics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>10903 New Hampshire Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>White Oak Building 66\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Silver Spring\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20993\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER CMS #673150\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 07, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Manmeet Maggu:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Mississauga, Ontario, Canada on June 3 through June 5, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Trexo Home and Trexo Plus medical devices, hereafter referred to as the Trexo devices, and offers the product for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Based on the evidence collected during the June 2023 inspection and other information, including statements on your firm’s website, www.trexorobotics.com, last reviewed on October 05, 2023, FDA has determined that the Trexo devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Trexo devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction this device into interstate commerce for commercial distribution without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81.\u003C\u002Fp>\n\n\u003Cp>You have listed the Trexo devices under classification regulation 21 CFR 890.1925. Devices classified under 21 CFR 890.1925, Isokinetic Testing and Evaluation System, are exempt from premarket notification unless they exceed the limitations of exemption at 21 CFR 890.9(a). Based on evidence collected during FDA’s inspection and a review of your firm’s website, FDA has determined that the Trexo devices are intended for uses that are different from those of legally marketed devices in the generic type of device under 21 CFR 890.1925, Isokinetic Testing and Evaluation System. Generic devices of this type are rehabilitative exercise devices intended for medical purposes, such as to measure, evaluate, and increase the strength of muscles&nbsp;and the range of motion of joints. However, your firm is marketing the Trexo devices for a different intended use; specifically, as a robotic powered gait training device to assist children with different levels of disability with ambulatory functions such as walking and standing. For example, statements made by your firm in labeling include the following:\u003C\u002Fp>\n\n\u003Cp>• “Introducing Trexo Robotic legs to help children with mobility challenges get upright and walk independently.”\u003Cbr>\n• “Depending on your child’s needs, you may adjust the amount of weight bearing, the gait pattern, speed of the device, and level of assist. The active assist feature may be used by children who have some ability to initiate steps or walk.”\u003C\u002Fp>\n\n\u003Cp>Because the Trexo is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.1925, it exceeds the limitations described in 21 CFR 890.9(a) thus requires approval prior to marketing.\u003C\u002Fp>\n\n\u003Cp>In addition, your device appears to operate using a different fundamental scientific technology than legally marketed devices in the generic type of device under 21 CFR 890.1925. For example, based on information in the product manual, the Trexo device use actuators such as a “powered hip joint” (part #1) and a “powered knee joint” (part #5) to generate forces or torques to the swing leg that assist human movement. In contrast, devices classified under 21 CFR 890.1925 are typically stationary machines that consist of a chair or a bench with a resistance mechanism that allows for controlled resistance for measuring muscular performance such as strength, power, and resistance. To the extent the Trexo devices operate using different fundamental scientific technology than legally marketed devices in the generic type of device under 890.1925, they also exceed the limitations of exemption from section 510(k) of the Act as described in 21 CFR 890.9(b).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Manmeet Maggu dated June 30, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm’s procedures, QMS-S09-730-2, Design and Development Control, Rev 2 (Dated June 7, 2023) and QMS-S09-730-2, Design and Development Control, Rev 1 (Dated May 13, 2023), do not ensure that the design control process has been followed for the Trexo Home and Trexo Plus devices or that design validation was performed under defined operating conditions on the initial production units or the results from design validation were documented in the Device History File (DHF) of the devices.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate.\u003C\u002Fp>\n\n\u003Cp>Your firm indicated that CAR-39 is related to this observation. The proposed corrective actions include: 1) your firm will be continuing with design change activities according to QMS-SOP-730-1, Design and Development Control, and 2) QMS-PLN-003, Trexo Home\u002FPlus Verification and Validation Plan, will be revised to implement design change activities with a proposed completion target date of November 30, 2023. The review of the cited procedure, QMS-SOP-730-1, Design and Development Control, does not address all of the requirements for 21 CFR 820.30. For example, this procedure does not clearly explain how your firm used change control during its design process or how approved design inputs are implemented as part of the change control process.\u003C\u002Fp>\n\n\u003Cp>Additionally, the review of the QMS-PLN-003, Trexo Home\u002FPlus Verification and Validation Plan, revealed that this procedure does not address all of the requirements for 21 CFR 820.30(g). For example, this procedure did not summarize how the clinical evaluations of the device ensure the device meets user needs and the intended uses, and this procedure did not clearly define how risk management issues were addressed throughout the design control process for these devices. In addition, it is unclear what design change activities are being conducted and how these design change activities will result in the revision of the QMS-PLN-003.\u003C\u002Fp>\n\n\u003Cp>Your firm should provide evidence that the procedure has been updated to include all of the requirements of 21 CFR 820.30, and evidence of implementation of the validation activities that were conducted as part of the design control process for the Trexo devices.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example: The procedure, QMS-SOP-756-1, Process Validation, Rev 1.0 (dated June 6, 2023) does not ensure that a process that cannot be fully verified has been adequately validated. For example, the PCBA and motor tests for the Trexo Home and Trexo Plus have not been validated.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate.\u003C\u002Fp>\n\n\u003Cp>Your firm indicated that CAR-53 is related to this observation. The proposed corrective actions include: 1) drafting QMS-DOC-756.001, Required Process Validations, to list all of the processes that require validation and 2) to implement the Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) activities that were specified in QMS-DOC-756.001. Your firm did not indicate if the procedure, QMS-SOP-756-1, Process Validation, would be updated to meet the requirements of 21 CFR 820.75(a). In addition, a copy of the QMS-DOC-756.001 document was not provided for review. Without this document, it is unknown what IQ, OQ and PQ activities are being performed on the Trexo devices. In addition, your firm did not specifically address the criteria that will be utilized in order to conduct the PCBA and motor validation tests\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. Appropriate statistical methodology shall be employed where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1).\u003C\u002Fp>\n\n\u003Cp>For example: The procedure, QMS-S09-851-0, Corrective and Preventative Actions (CAPA), Rev. 2 (dated May 1, 2023; and the same procedure, Rev 1, dated April 14, 2023) does not ensure that all data sources are reviewed as possible CAPAs. For example, non-conformance reports (NCRs) are not included as a Quality Objective.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate.\u003C\u002Fp>\n\n\u003Cp>Your firm indicated that CAR-59 has been initiated in response to this observation. The proposed corrective actions are: 1) to update QMS-DOC-001, Quality Policy &amp; Quality Objectives, to include measurable Key Performance Indicator (KPI) reporting metrics required for NCRs and CAPAs; 2) to revise CEMS-SOP-851-2, Corrective and Preventative Actions, to include all data sources. Your firm did not provide copies of the updated procedures, QMS-DOC-001, Quality Policy &amp; Quality Objectives and QMS-S09-851-0, Corrective and Preventative Actions for review. Your firm’s response does not mention if the updated procedures will be utilized to conduct a retrospective review of past NCRs and CAPAs.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit. Such procedures shall ensure that: 1) All complaints are processed in a uniform and timely manner; 2) Oral complaints are documented upon receipt; and 3) Complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting (MDR), as required by 21 CFR 820.198(a).\u003C\u002Fp>\n\n\u003Cp>For example: The procedures, QMS-SOP-821-2, Feedback and Complaint Handling, Rev 2 (dated May 17, 2023 (and the previous version, Rev 1 dated April 21, 2023)) and QMS-WRK-821-1, Feedback and Complaint Work Instructions, Rev 1 (dated June 2, 2023) do&nbsp;not ensure that complaints received by your firm are adequately handled. Specifically:\u003C\u002Fp>\n\n\u003Cp>A. Your procedures do not ensure that all complaints are handled as complaints instead of feedback. Each of the four feedback records should have been designated as complaints but were instead handled as feedback. Feedback records do not require evaluation for MDRs.\u003C\u002Fp>\n\n\u003Cp>B. Your procedures do not ensure complaints that do not require investigations are documented. Five out of seven complaints reviewed did not require investigations due to the investigations being previously investigated. This information was not documented in the five complaints.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time.\u003C\u002Fp>\n\n\u003Cp>Your firm indicated that CAR-46 is related to this observation. The proposed corrective actions are: 1) to retrain the Customer Service Engineer (CSE) on the Feedback and Complaint Handling procedure, QMS-SOP-821-2; 2) to review past tickets to ensure that the tickets were handled correctly as complaints, to evaluate these tickets for compliance with the MDR procedure, and to investigate these tickets (if required); 3) to update the Feedback and Complaint Report, QMS-FRM-821, to reference an ISSUE ID (ISSUE ID group the complaints based on the causes of the complaints); and 4) to update the Feedback and Complaint Work Instruction, QMS-WRK-821, to describe the process of grouping a new complaint to an existing ISSUE ID in order to determine if an investigation is necessary. Without all of the aforementioned supporting evidence, the evidence needed to evaluate the adequacy of this response is incomplete.\u003C\u002Fp>\n\n\u003Cp>Our office requests that your firm, Trexo Robotics Holdings Inc., cease any activities that result in the misbranding or adulteration of the Trexo devices, such as the commercial distribution of the devices for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this&nbsp;Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to: CDRHWarningLetterResponses@fda.hhs.gov or by mail to:&nbsp;\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the identification number CMS #673150 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Heather Dean, Ph.D., Assistant Director, Physical Medicine-Acute Injury Devices Team at (240) 402-9874.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCAPT Nina Mezu-Nwaba, PharmD., MPH., MSc.\u003Cbr>\nDeputy Director\u003Cbr>\nOHT5: Office of Neurological\u003Cbr>\nand Physical Medicine Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nManmeet Maggu\n\nTrexo Robotics Holdings Inc.\n\n6705 Millcreek Drive, Unit 3\n\nMississauga ON L5N 5M4\n\nCanada\n\n(b)(6)@trexorobotics.com\n\nIssuing Office:\n\n\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"\n\n10903 New Hampshire Ave.\n\nWhite Oak Building 66\n\nSilver Spring, MD 20993\n\nUnited States\n\nWARNING LETTER CMS #673150\n\nFebruary 07, 2024\n\nDear Manmeet Maggu:\n\nDuring an inspection of your firm located in Mississauga, Ontario, Canada on June 3 through June 5, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Trexo Home and Trexo Plus medical devices, hereafter referred to as the Trexo devices, and offers the product for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nBased on the evidence collected during the June 2023 inspection and other information, including statements on your firm’s website, www.trexorobotics.com, last reviewed on October 05, 2023, FDA has determined that the Trexo devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Trexo devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction this device into interstate commerce for commercial distribution without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81.\n\nYou have listed the Trexo devices under classification regulation 21 CFR 890.1925. Devices classified under 21 CFR 890.1925, Isokinetic Testing and Evaluation System, are exempt from premarket notification unless they exceed the limitations of exemption at 21 CFR 890.9(a). Based on evidence collected during FDA’s inspection and a review of your firm’s website, FDA has determined that the Trexo devices are intended for uses that are different from those of legally marketed devices in the generic type of device under 21 CFR 890.1925, Isokinetic Testing and Evaluation System. Generic devices of this type are rehabilitative exercise devices intended for medical purposes, such as to measure, evaluate, and increase the strength of muscles and the range of motion of joints. However, your firm is marketing the Trexo devices for a different intended use; specifically, as a robotic powered gait training device to assist children with different levels of disability with ambulatory functions such as walking and standing. For example, statements made by your firm in labeling include the following:\n\n• “Introducing Trexo Robotic legs to help children with mobility challenges get upright and walk independently.”\n\n• “Depending on your child’s needs, you may adjust the amount of weight bearing, the gait pattern, speed of the device, and level of assist. The active assist feature may be used by children who have some ability to initiate steps or walk.”\n\nBecause the Trexo is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.1925, it exceeds the limitations described in 21 CFR 890.9(a) thus requires approval prior to marketing.\n\nIn addition, your device appears to operate using a different fundamental scientific technology than legally marketed devices in the generic type of device under 21 CFR 890.1925. For example, based on information in the product manual, the Trexo device use actuators such as a “powered hip joint” (part #1) and a “powered knee joint” (part #5) to generate forces or torques to the swing leg that assist human movement. In contrast, devices classified under 21 CFR 890.1925 are typically stationary machines that consist of a chair or a bench with a resistance mechanism that allows for controlled resistance for measuring muscular performance such as strength, power, and resistance. To the extent the Trexo devices operate using different fundamental scientific technology than legally marketed devices in the generic type of device under 890.1925, they also exceed the limitations of exemption from section 510(k) of the Act as described in 21 CFR 890.9(b).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Manmeet Maggu dated June 30, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\n\nFor example: Your firm’s procedures, QMS-S09-730-2, Design and Development Control, Rev 2 (Dated June 7, 2023) and QMS-S09-730-2, Design and Development Control, Rev 1 (Dated May 13, 2023), do not ensure that the design control process has been followed for the Trexo Home and Trexo Plus devices or that design validation was performed under defined operating conditions on the initial production units or the results from design validation were documented in the Device History File (DHF) of the devices.\n\nWe reviewed your firm’s response and concluded that it is not adequate.\n\nYour firm indicated that CAR-39 is related to this observation. The proposed corrective actions include: 1) your firm will be continuing with design change activities according to QMS-SOP-730-1, Design and Development Control, and 2) QMS-PLN-003, Trexo Home\u002FPlus Verification and Validation Plan, will be revised to implement design change activities with a proposed completion target date of November 30, 2023. The review of the cited procedure, QMS-SOP-730-1, Design and Development Control, does not address all of the requirements for 21 CFR 820.30. For example, this procedure does not clearly explain how your firm used change control during its design process or how approved design inputs are implemented as part of the change control process.\n\nAdditionally, the review of the QMS-PLN-003, Trexo Home\u002FPlus Verification and Validation Plan, revealed that this procedure does not address all of the requirements for 21 CFR 820.30(g). For example, this procedure did not summarize how the clinical evaluations of the device ensure the device meets user needs and the intended uses, and this procedure did not clearly define how risk management issues were addressed throughout the design control process for these devices. In addition, it is unclear what design change activities are being conducted and how these design change activities will result in the revision of the QMS-PLN-003.\n\nYour firm should provide evidence that the procedure has been updated to include all of the requirements of 21 CFR 820.30, and evidence of implementation of the validation activities that were conducted as part of the design control process for the Trexo devices.\n\n2. Failure to adequately establish and maintain procedures where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\n\nFor example: The procedure, QMS-SOP-756-1, Process Validation, Rev 1.0 (dated June 6, 2023) does not ensure that a process that cannot be fully verified has been adequately validated. For example, the PCBA and motor tests for the Trexo Home and Trexo Plus have not been validated.\n\nWe reviewed your firm’s response and concluded that it is not adequate.\n\nYour firm indicated that CAR-53 is related to this observation. The proposed corrective actions include: 1) drafting QMS-DOC-756.001, Required Process Validations, to list all of the processes that require validation and 2) to implement the Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) activities that were specified in QMS-DOC-756.001. Your firm did not indicate if the procedure, QMS-SOP-756-1, Process Validation, would be updated to meet the requirements of 21 CFR 820.75(a). In addition, a copy of the QMS-DOC-756.001 document was not provided for review. Without this document, it is unknown what IQ, OQ and PQ activities are being performed on the Trexo devices. In addition, your firm did not specifically address the criteria that will be utilized in order to conduct the PCBA and motor validation tests\n\n3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. Appropriate statistical methodology shall be employed where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1).\n\nFor example: The procedure, QMS-S09-851-0, Corrective and Preventative Actions (CAPA), Rev. 2 (dated May 1, 2023; and the same procedure, Rev 1, dated April 14, 2023) does not ensure that all data sources are reviewed as possible CAPAs. For example, non-conformance reports (NCRs) are not included as a Quality Objective.\n\nWe reviewed your firm’s response and concluded that it is not adequate.\n\nYour firm indicated that CAR-59 has been initiated in response to this observation. The proposed corrective actions are: 1) to update QMS-DOC-001, Quality Policy & Quality Objectives, to include measurable Key Performance Indicator (KPI) reporting metrics required for NCRs and CAPAs; 2) to revise CEMS-SOP-851-2, Corrective and Preventative Actions, to include all data sources. Your firm did not provide copies of the updated procedures, QMS-DOC-001, Quality Policy & Quality Objectives and QMS-S09-851-0, Corrective and Preventative Actions for review. Your firm’s response does not mention if the updated procedures will be utilized to conduct a retrospective review of past NCRs and CAPAs.\n\n4. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit. Such procedures shall ensure that: 1) All complaints are processed in a uniform and timely manner; 2) Oral complaints are documented upon receipt; and 3) Complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting (MDR), as required by 21 CFR 820.198(a).\n\nFor example: The procedures, QMS-SOP-821-2, Feedback and Complaint Handling, Rev 2 (dated May 17, 2023 (and the previous version, Rev 1 dated April 21, 2023)) and QMS-WRK-821-1, Feedback and Complaint Work Instructions, Rev 1 (dated June 2, 2023) do not ensure that complaints received by your firm are adequately handled. Specifically:\n\nA. Your procedures do not ensure that all complaints are handled as complaints instead of feedback. Each of the four feedback records should have been designated as complaints but were instead handled as feedback. Feedback records do not require evaluation for MDRs.\n\nB. Your procedures do not ensure complaints that do not require investigations are documented. Five out of seven complaints reviewed did not require investigations due to the investigations being previously investigated. This information was not documented in the five complaints.\n\nThe adequacy of your firm’s response cannot be determined at this time.\n\nYour firm indicated that CAR-46 is related to this observation. The proposed corrective actions are: 1) to retrain the Customer Service Engineer (CSE) on the Feedback and Complaint Handling procedure, QMS-SOP-821-2; 2) to review past tickets to ensure that the tickets were handled correctly as complaints, to evaluate these tickets for compliance with the MDR procedure, and to investigate these tickets (if required); 3) to update the Feedback and Complaint Report, QMS-FRM-821, to reference an ISSUE ID (ISSUE ID group the complaints based on the causes of the complaints); and 4) to update the Feedback and Complaint Work Instruction, QMS-WRK-821, to describe the process of grouping a new complaint to an existing ISSUE ID in order to determine if an investigation is necessary. Without all of the aforementioned supporting evidence, the evidence needed to evaluate the adequacy of this response is incomplete.\n\nOur office requests that your firm, Trexo Robotics Holdings Inc., cease any activities that result in the misbranding or adulteration of the Trexo devices, such as the commercial distribution of the devices for the uses discussed above.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to: CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the identification number CMS #673150 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Heather Dean, Ph.D., Assistant Director, Physical Medicine-Acute Injury Devices Team at (240) 402-9874.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCAPT Nina Mezu-Nwaba, PharmD., MPH., MSc.\n\nDeputy Director\n\nOHT5: Office of Neurological\n\nand Physical Medicine Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Trexo Robotics Holdings Inc.","trexo-robotics-holdings-inc-673150-02072024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrexo-robotics-holdings-inc-673150-02072024","2026-10-26T08:10:14.765948+00:00","Warning Letter","Issued","2024-06-04","673150","Medical Devices","\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"","Manmeet Maggu","2026-08-20T00:03:38.973+00:00","VIA Electronic Mail","2024-02-07",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":23,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":51,"body_fetched_at":52,"delivery_method":19,"recipient_title":19,"reference_number":53,"action_taken_date":54,"medical_device_id":19,"response_letter_date":19},1621,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2024-02-06T14:20:00Z\">02\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-02T05:00:00Z\">02\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fehy-holdings-llc-675591-02022024\">Ehy Holdings, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Register and List\u003Cbr \u002F>\r\n","Failure to Register and List","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>WL 2642\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jabez Liu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Ehy Holdings, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3483 Pleasant Ridge Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wingdale\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>12594\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:zjksiopqiduj@wilson.ntesmail.com\"> zjksiopqiduj@wilson.ntesmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 2, 2024\u003C\u002Fp>\n\n\u003Cp>RE: WL #2642\u003C\u002Fp>\n\n\u003Cp>Dear Jabez Liu:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for the following drug products\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>:\u003C\u002Fp>\n\n\u003Cp>81799-001&nbsp; &nbsp;Nicotine Transdermal Patches\u003Cbr>\n81799-002&nbsp; &nbsp;Nicotine Transdermal Patches\u003Cbr>\n81799-003&nbsp; &nbsp;Nicotine Transdermal Patches\u003Cbr>\n81799-004&nbsp; &nbsp;Wart Remover\u003Cbr>\n81799-005&nbsp; &nbsp;Herpes Relief Cream\u003Cbr>\n81799-006&nbsp; &nbsp;Seborrheic Dermatitis and Psoriasis Cream\u003Cbr>\n81799-007&nbsp; &nbsp;Seborrheic Dermatitis and Psoriasis\u003Cbr>\n81799-008&nbsp; &nbsp;Nupharmisto Tattoo Numbing Cream\u003Cbr>\n81799-009&nbsp; &nbsp;Shingles Pain Relief Cream\u003Cbr>\n81799-010&nbsp; &nbsp;Nupharmisto Psoriasis Eczema Cream\u003C\u002Fp>\n\n\u003Cp>Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, these drugs are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C 352(o). Introduction or delivery for introduction of such misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. The listing file for drug listings must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&amp;C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for the aforementioned drug listings, the manufacturer referenced is identified as Ehy Holdings, LLC (DUNS 117322715). After review of your June 27, 2023 communication with FDA’s Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ), it was revealed that Ehy Holdings, LLC is not currently involved in the manufacturing processes of drugs that are being distributed in U.S. commercial distribution nor imported or offered for import into the United States and therefore, should not be registered as a manufacturer. Consequently, the listings for these drug products are not referencing a correct or active registered manufacturing establishment and no listing updates have been provided.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\n\n\u003Cp>In addition, Nicotine Transdermal Patches (NDC 81799-001), Nicotine Transdermal Patches (NDC 81799-002), Nicotine Transdermal Patches (NDC 81799-003), Wart Remover (NDC 81799-004), Herpes Relief Cream (NDC 81799-005), Seborrheic Dermatitis and Psoriasis Cream (NDC 81799-006), Seborrheic Dermatitis and Psoriasis (NDC 81799-007), Nupharmisto Tattoo Numbing Cream (NDC 81799-008), Shingles Pain Relief Cream (NDC 81799-009), and Nupharmisto Psoriasis Eczema Cream (NDC 81799-010) are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2642 on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith, Director\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>CC: orapharm1opdiv1mgmt@fda.hhs.gov\u003Cbr>\nAttn: Director of Compliance\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>On December 1, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 15, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Reference #:\n\nWL 2642\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJabez Liu\n\nEhy Holdings, LLC\n\n3483 Pleasant Ridge Road\n\nWingdale, NY 12594\n\nUnited States\n\nzjksiopqiduj@wilson.ntesmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nFebruary 2, 2024\n\nRE: WL #2642\n\nDear Jabez Liu:\n\nThis letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for the following drug products1:\n\n81799-001 Nicotine Transdermal Patches\n\n81799-002 Nicotine Transdermal Patches\n\n81799-003 Nicotine Transdermal Patches\n\n81799-004 Wart Remover\n\n81799-005 Herpes Relief Cream\n\n81799-006 Seborrheic Dermatitis and Psoriasis Cream\n\n81799-007 Seborrheic Dermatitis and Psoriasis\n\n81799-008 Nupharmisto Tattoo Numbing Cream\n\n81799-009 Shingles Pain Relief Cream\n\n81799-010 Nupharmisto Psoriasis Eczema Cream\n\nYour firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&C Act), 21 U.S.C 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, these drugs are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C 352(o). Introduction or delivery for introduction of such misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C 331(a). These violations are described in more detail below.\n\nRegistration and Drug Listing Violations\n\nSection 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. The listing file for drug listings must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for the aforementioned drug listings, the manufacturer referenced is identified as Ehy Holdings, LLC (DUNS 117322715). After review of your June 27, 2023 communication with FDA’s Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ), it was revealed that Ehy Holdings, LLC is not currently involved in the manufacturing processes of drugs that are being distributed in U.S. commercial distribution nor imported or offered for import into the United States and therefore, should not be registered as a manufacturer. Consequently, the listings for these drug products are not referencing a correct or active registered manufacturing establishment and no listing updates have been provided.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\n\nIn addition, Nicotine Transdermal Patches (NDC 81799-001), Nicotine Transdermal Patches (NDC 81799-002), Nicotine Transdermal Patches (NDC 81799-003), Wart Remover (NDC 81799-004), Herpes Relief Cream (NDC 81799-005), Seborrheic Dermatitis and Psoriasis Cream (NDC 81799-006), Seborrheic Dermatitis and Psoriasis (NDC 81799-007), Nupharmisto Tattoo Numbing Cream (NDC 81799-008), Shingles Pain Relief Cream (NDC 81799-009), and Nupharmisto Psoriasis Eczema Cream (NDC 81799-010) are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2642 on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith, Director\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nCC: orapharm1opdiv1mgmt@fda.hhs.gov\n\nAttn: Director of Compliance\n\n_________________________\n\n1On December 1, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 15, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).","Ehy Holdings, LLC","ehy-holdings-llc-675591-02022024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fehy-holdings-llc-675591-02022024","2026-10-26T08:08:31.724605+00:00","2024-02-06","675591","Drugs","Jabez Liu","2026-08-20T00:19:09.056+00:00","WL 2642","2024-02-02",{"id":56,"raw":57,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":19,"letter_url":68,"updated_at":69,"action_type":22,"case_status":23,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":19,"issuing_office":61,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":19,"reference_number":19,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},2464,[58,59,60,61,62,13,13,13],"\u003Ctime datetime=\"2022-09-06T13:20:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-26T04:00:00Z\">08\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmuuv-holdings-inc-640705-08262022\">MUUV Holdings Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael T. Banta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>MUUV Holdings Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>43 Rainey St. Apt 2605\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78701-4450\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@muuvpouches.com\"> info@muuvpouches.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 26, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Michael T. Banta:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fmuuvpouches.com and determined that the nicotine pouch products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the websitehttps:\u002F\u002Fmuuvpouches.com revealed that you manufacture and offer for sale or distribution to customers in the United States nicotine pouch products without a marketing authorization order, including: Wintergreen, Mint, and Citrus nicotine pouches.\u003C\u002Fp>\n\n\u003Cp>The nicotine pouch products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201844, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Mallory Johnson at (240) 402- 4709 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Contact Privacy Inc. Customer 0161932284\u003Cbr>\nMuuvpouches.com@contactprivacy.com\u003C\u002Fp>\n\n\u003Cp>Tucows Domains, Inc.\u003Cbr>\ndomainabuse@tucows.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMichael T. Banta\n\nMUUV Holdings Inc.\n\n43 Rainey St. Apt 2605\n\nAustin, TX 78701-4450\n\nUnited States\n\ninfo@muuvpouches.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 26, 2022\n\nWARNING LETTER\n\nDear Michael T. Banta:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fmuuvpouches.com and determined that the nicotine pouch products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the websitehttps:\u002F\u002Fmuuvpouches.com revealed that you manufacture and offer for sale or distribution to customers in the United States nicotine pouch products without a marketing authorization order, including: Wintergreen, Mint, and Citrus nicotine pouches.\n\nThe nicotine pouch products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201844, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Mallory Johnson at (240) 402- 4709 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nContact Privacy Inc. Customer 0161932284\n\nMuuvpouches.com@contactprivacy.com\n\nTucows Domains, Inc.\n\ndomainabuse@tucows.com\n\nShopify, Inc.\n\nabuse@shopify.com","MUUV Holdings Inc.","muuv-holdings-inc-640705-08262022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmuuv-holdings-inc-640705-08262022","2026-10-26T08:09:28.804465+00:00","2022-09-06","640705","Tobacco","Michael T. Banta","2026-08-20T01:37:01.606+00:00","VIA UPS and Electronic Mail","2022-08-26",3,{"510k":79,"classification":80,"enforcement":81,"event":82,"event_backfill":83,"pma":84,"warning_letter":85},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]